Jinan Guo1, Jianggen Yang1, Xuhui Zhang2, Xiaoyan Feng2, Heqiu Zhang2, Lingwu Chen3, Heather Johnson4, Jenny L Persson5,6, Kefeng Xiao7. 1. Department of Urology, The Second Clinical Medical College of Jinan University (Shenzhen People's Hospital), Shenzhen Urology Minimally Invasive Engineering Center, Shenzhen, P.R. China. 2. Department of Bio-diagnosis, Institute of Basic Medical Sciences, Beijing, P.R. China. 3. Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, P.R. China. 4. Olympia Diagnostics, Inc., Sunnyvale, CA, U.S.A. 5. Department of Translational Medicine, Lund University, Malmö, Sweden jenny_l.persson@med.lu.se kevin5510315@qq.com. 6. Department of Molecular Biology, Umeå University, Umeå, Sweden. 7. Department of Urology, The Second Clinical Medical College of Jinan University (Shenzhen People's Hospital), Shenzhen Urology Minimally Invasive Engineering Center, Shenzhen, P.R. China jenny_l.persson@med.lu.se kevin5510315@qq.com.
Abstract
BACKGROUND/AIM: Prostate cancer (PCa) diagnosis using patient urine samples represents a non-invasive and more convenient method than the conventional biopsy and prostate-specific antigen (PSA) test. This study intended to identify a biomarker panel to distinguish PCa from benign prostate using urine samples. MATERIALS AND METHODS: We identified six biomarkers with differential gene expression in 154 PCa and benign prostate specimens. We then determined mRNA expression signature and the diagnostic performance of the 6-biomarker panel in 156 urine samples from patients with PCa and benign disease. RESULTS: The 6-biomarker panel distinguished PCa from benign prostate cases with sensitivity of 80.6%, specificity of 62.9% and area under the curve (AUC) of 0.803 (p<0.0001), whereas serum PSA at 4 ng/ml cutoff had sensitivity of 95.5%, specificity of 20.2% and AUC of 0.521 (p<0.0001). CONCLUSION: The 6-biomarker panel for use in urine samples was able to distinguish PCa from benign prostate with higher specificity and accuracy than PSA and may be useful in clinical settings. Copyright
BACKGROUND/AIM: Prostate cancer (PCa) diagnosis using patient urine samples represents a non-invasive and more convenient method than the conventional biopsy and prostate-specific antigen (PSA) test. This study intended to identify a biomarker panel to distinguish PCa from benign prostate using urine samples. MATERIALS AND METHODS: We identified six biomarkers with differential gene expression in 154 PCa and benign prostate specimens. We then determined mRNA expression signature and the diagnostic performance of the 6-biomarker panel in 156 urine samples from patients with PCa and benign disease. RESULTS: The 6-biomarker panel distinguished PCa from benign prostate cases with sensitivity of 80.6%, specificity of 62.9% and area under the curve (AUC) of 0.803 (p<0.0001), whereas serum PSA at 4 ng/ml cutoff had sensitivity of 95.5%, specificity of 20.2% and AUC of 0.521 (p<0.0001). CONCLUSION: The 6-biomarker panel for use in urine samples was able to distinguish PCa from benign prostate with higher specificity and accuracy than PSA and may be useful in clinical settings. Copyright